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Abstract Apoptosis is an important mechanism of malignant
tumor formation and progression. Single nucleotide polymor-
phisms (SNPs) located within cell death genes may influence
cancer risk. We explored the relationship between FasL
−844T/C and/or Fas −1377G/A SNPs and pulmonary adeno-
carcinoma (AD). Two hundred seventy-five patients with pul-
monary AD of South China admitted into Zhejiang Cancer
Hospital from July 2007 to October 2011 were randomly se-
lected, and their clinicopathological data were collected at the
same time. Two hundred ninety-seven cases of healthy indi-
viduals were selected as control. FasL −844T/C and Fas
−1377G/A SNPs were detected by PCR-RFLP technique to
evaluate the relationships between these two SNPs and pul-
monary AD. Age, FasL −844 and Fas −1377 SNPs were as-
sociated with increased risk of pulmonary AD susceptibility in
main effect analysis. FasL −844CC and Fas −1377 AAwere
associated with an increased risk for the development of pul-
monary AD only in age <60 years people, but not in those
≥60 years. FasL −844CC genotype was associated with an
increased risk for pulmonary AD (adjusted OR=2.010, 95 %
CI 1.196–3.379, P=0.008) compared with TT genotype.
However, Fas −1377 AA was a risk factor only when FasL
−844 genotype was CC. Fas −1377 genotypes showed signif-
icant effect modification of pulmonary AD risk by FasL −844
genotype with test of the interaction term adjusting for age,
gender, and FasL −844 SNP. Fas −1377G/Awas not associat-
ed with the clinicopathological factors, while FasL −844C/T
was associated with tumor stage and lymph node metastasis in
age ≥60 years people and tumor stage in those <60 years. In
conclusion, FasL −844 SNP is associated with the susceptibil-
ity of pulmonary AD in age <60 years people. Fas −1377 SNP
maymodify the association of FasL −844 SNPwith the risk of
pulmonary AD. FasL −844 genotype plays an important role
in the occurrence and progression of pulmonary AD.
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Introduction
Lung cancer is the most common primary malignancy and the
leading cause of cancer-related deaths worldwide [1]. Non-
small cell lung cancer (NSCLC) accounts for 85 % of all lung
cancers. Adenocarcinoma (AD) accounts for 50 % of NSCLC
cases. It is one of the most frequent histologic subtypes and
presently the most common type in most countries. Since 30–
40 years ago, the incidence of AD has increased steadily [2,
3].
Approximately 80–90% of lung carcinomas are associated
with the carcinogenetic effect of smoking [4]. However, only
about 10–15 % of all smokers fall ill on lung cancer. On the
other side, 10–15 % of all lung carcinomas occur in non-
smokers [5]. These facts indicate that there is individual sus-
ceptibility to lung carcinogens as well as to development of
disorders. Genetic and environmental factors essentially influ-
ence the risk of lung cancer genesis, while molecular
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pathophysiology of genetic-environmental interaction is com-
plex and only partly identified up to now. That is why it is so
important to explore, whether individual difference in suscep-
tibility to lung cancer genesis has a genetic background.
Acquired ability to resist apoptosis is a common hallmark
of various types of malignant diseases, and the regulatory
defects of components of the apoptosis pathway contribute
to tumorigenesis, tumor cell invasion, and metastasis [6, 7].
Genetic variations of crucial genes in this cell-death pathway
may thus influence the susceptibility to cancer. The Fas–Fas
ligand (FasL) system is recognized as a major pathway for the
induction of apoptosis in cells and tissues [8]. Fas interacts
with FASL to initiate the death signal cascade and activate the
apoptosis signaling pathway. Fas and FasL molecules play an
important role in immune escape [9]. Decreased expression of
Fas and/or increased expression of FasL is associated with
different malignancies and may favor malignant transforma-
tion and progression [10].
Single nucleotide polymorphisms (SNPs) have been pro-
posed to play an important role in the genetic susceptibility to
cancer. Many gene SNPs can impact the risk of cancer. The
functional mutations in the Fas/FasL genes that impair apo-
ptotic signal transduction have been shown to be associated
with an increased risk of many types of cancers [11–15]. The
Fas/FasL system may be significant in cancer initiation, de-
velopment, and progression, and SNPs, which possess the
potential to alter the expression of Fas and/or FasL, have been
proposed to be significant in the genetic susceptibility to
cancer.
We have studied the clinical significances of FasL −844T/
C and Fas −1377G/A mutation in esophageal carcinoma [16].
Now, we want to analyze whether FasL −844T/C and Fas
−1377G/A polymorphism influence the susceptibility or clin-
icopathological factor of pulmonary AD.
Materials and methods
Subjects
Patients with histopathologically confirmed pulmonary
AD (n=275) were recruited from Zhejiang Cancer Hos-
pital, affiliated hospital of Zhejiang Medical College,
China, between July 2007 and October 2011. Control
subjects (n=297) were cancer-free individuals who had
been randomly selected from medical examination cen-
ter. All subjects were unrelated ethnic Han Chinese and
residents in South China. There was no sex and age
restriction. Before recruitment, a standard questionnaire
had been administered through face-to-face interviews
by trained interviewers to obtain information on demo-
graphic data and related factors. At recruitment, written
informed consent was obtained from each subject to
consent to participate in the study and to allow their
biological samples to be genetically analyzed. This re-
search was approved by the Medical Ethics Committee,
Zhejiang Cancer Hospital.
All patients underwent radical resection and had de-
tailed clinicopathological data. The tumor staging was
determined according to UICC 2009 7th Edition. The
presence or absence of lymph node metastasis was eval-
uated according to the tumor node metastasis classifica-
tion on the basis of postoperative histopathologic exam-
ination of pulmonary AD specimens. Other clinical data
(age at diagnosis, sex, tumor length) and tumor biolog-
ical data (grading, visceral pleura, vascular tumor
thrombus) were also documented.
Table 1 Baseline clinical characteristics and the genotypic and allelic






Gender male 147 179 2.705 0.100
female 128 118
Age <60 119 192 26.293 0.000**
≥60 156 105




TT 32 (11.6) 52 (17.5) 8.692 0.013*
TC 103 (37.5) 128 (43.1)
CC 140 (50.9) 117 (39.4)
Alleles T allele 167 (30.4) 232 (39.1) 9.503 0.002**
C allele 383 (69.6) 362 (60.9)
Fas −1377
Genotypes
GG 89 (32.4) 121 (40.7) 6.605 0.037*
GA 133 (48.4) 138 (46.5)
AA 53 (19.3) 38 (12.8)
Alleles G allele 311 (56.5) 380 (64.0) 6.587 0.010*
A allele 239 (43.5) 214 (36.0)
*P<0.05; **P<0.01


























0.011 1.364 (1.065–1.746)c 0.014
aAdjusting for gender, smoking status, FasL −844, and Fas −1377 SNP
bAdjusting for age, gender, smoking status, and Fas −1377 SNP
cAdjusting for age, gender, smoking status, and FasL −844 SNP
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Genotyping
After signing informed consent forms, each subject donated
3 mL of blood to be used for genomic DNA extraction.
Genomic DNAwas extracted from peripheral blood using
Blood Genome DNA Extraction Kit (Takara Biotechnology
Co. Ltd., Dalian). The −844T/C polymorphism of FasL was
detected using PCR-RFLP. DNA fragments were amplified in
a total volume of 100 μL PCRs containing PCR Premix 50μL
(BioTeke Corporation, Beijing, China), forward primer (5′-
CAGCTACTCGG AGGCCAAG-3′) 1 μL, reverse primer
(5′-GCTCTGAGGGGAGAGACCAT-3′) 1 μL, DDW
46 μL, and DNA 2 μL. Amplification was carried out under
the following condition: 1 cycle of 2 min at 95 °C, 35 cycles of
30 s at 94 °C, 30 s at 62 °C, and 45 s at 72 °C, followed by
7 min at 72 °C. Amplified products were digested with BsrDI
(Fermentas, Thermo Fisher Scientific Inc.) at 55 °C for 4 h.
All products were loaded onto 3 % MS-6 Agarose (Takara
Biotechnology Co. Ltd., Dalian) and electrophoresed. Bands
were visualized and typed after GelRed (Biotium Company,
USA) staining. The PCR product amplified for the polymor-
phism was 410 bp. The BsrDI restriction enzymes were used
to distinguish −844T/C, resulting in 122- and 104-bp frag-
ments in the presence of the −844T allele.
Fas −1377G/A polymorphism in promoter region was also
detected with PCR-RFLP. The primers for amplification were
5′-TGTGTGCACAAGGCTGGCGC-3′ for forward primer
and 5′-TGCATCTGTCACTGCACTTACCACCA-3′ for re-
verse primer, which produce 122-bp fragment. To introduce
a restriction endonuclease site, 3′ end of forward primer was
changed from CAC to CGC, which created a BstUI site. The
procedure of amplification was the same as above. After PCR,
BstUI (New England Biolabs, USA) digestion generated frag-
ments of 104 and 18 bp for G allele.
The polymorphism analysis was performed by two persons
independently in a blind fashion. More than 10 % of the
Table 3 Association of genotypic and allelic frequencies of FasL −844 and Fas −1377 with pulmonary AD risk
Locus Crude OR (95 % CI) P value Adjusted ORa (95 % CI) P value
FasL −844 Genotypes
TT 1 1
TC 1.308 (0.784–2.180) 0.304 1.300 (0.769–2.198) 0.328
CC 1.944 (1.174–3.219) 0.010* 2.010 (1.196–3.379) 0.008**
Alleles
T allele 1 1
C allele 1.470 (1.150–1.7879) 0.002** 1.504 (1.169–1.936) 0.002**
Fas −1377 Genotypes
GG 1 1
GA 1.310 (0.912–1.883) 0.144 1.252 (0.860–1.823) 0.241
AA 1.377 (1.073–1.767) 0.012* 1.400 (1.083–1.809) 0.010*
Alleles
G allele 1 1
A allele 1.233 (0.938–1.620) 0.133 1.242 (0.937–1.646) 0.132
*P<0.05; **P<0.01
aAdjusting for age and gender
Table 4 Risk of pulmonary AD associated with FasL −844 genotypes by Fas −1377 genotypes
FasL −844 Fas −1377 Cases (%) (n=275) Controls (%) (n=297) Crude OR (95 % CI) P value Adjusted ORa (95 % CI) P value
TT + TC GG + GA 113 156 1 1
TT + TC AA 22 24 1.265 (0.676–2.369) 0.462 1.442 (0.750–2.774) 0.273
CC GG + GA 109 103 1.209 (1.009–1.449) 0.04 1.228 (1.016–1.484) 0.033
CC AA 31 14 1.451 (1.159–1.818) 0.01 1.519 (1.201–1.922) 0.000
CC GG + GA 109 103 1 1
CC AA 31 14 2.092 (1.054–4.156) 0.035 2.108 (1.025–4.337) 0.043
aAdjusting for age and gender
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samples were randomly selected for confirmation, and the
results were 100 % concordant.
Statistical analyses
Values were expressed as mean±SD or percent. To
check for genotyping error, we examined departure from
Hardy–Weinberg equilibrium (HWE) in controls, using
χ2 test. χ2 test analysis was used to detect these SNPs
in patients with pulmonary AD and health individuals.
The t test and χ2 test were used to detect age and sex
in the two groups, respectively.
Association between FasL −844T/C or Fas −1377G/A
polymorphism and pulmonary AD was assessed using
χ2 test. Pulmonary AD risk was estimated by odds ra-
tios (OR) and 95 % confidence intervals (CI) using
conditional logistic regression or multinomial logistic
regression controlling for age and gender. This codom-
inant model was defined as heterozygotes (1 variant
genotype) versus wild-type (0 variant genotype) or ho-
mozygotes (2 variant genotype) versus wild-type.
The relationships of these SNPs with the clinicopathologi-
cal parameters of patients were analyzed by χ2 test. We used
binary logistic regression (AscendantWald method) with each
parameter as dependant variable and genotypes of FasL
−844T/C or Fas −1377G/A polymorphism as independent
variables. Clinicopathological parameters were dichotomized
as follows: grading (well and moderately differentiation ver-
sus poorly differentiation), stage (stage I versus stages II–IIIa),
tumor length (less than and equal to 3 cm versus greater than
3 cm), visceral pleura, lymph node metastasis, and vascular
tumor thrombus (positive versus negative).
For stratified analyses, we created indicator variable
of age greater or less than 60 years old. Then, the
above statistical analyses were carried out at different
age groups.
All statistical testing was done at the two-sided 0.05 level
with SPSS 16.0 software.
Results
Gene polymorphisms and the association with pulmonary AD
This population-based case-control study included 275 pa-
tients with pulmonary AD and 297 control subjects. All study
subjects were south Chinese. Baseline clinical characteristics,
the genotype, and allele distributions of FasL and Fas poly-
morphisms in cases and controls are summarized in Table 1.
Cases were older than controls (P=0.000). The FasL
−844T/C and Fas −1377G/A genotype frequencies were all
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controls (χ2 =2.663, P=0.103; χ2 =0.019, P=0.890,
respectively).
Age, FasL −844, and Fas −1377 SNPs were associated
with increased risk of pulmonary AD susceptibility in main
effect analysis (Table 2).
Effect modification of the associations of the SNP
with pulmonary AD
Logistic regression analysis was used to estimate asso-
ciations between the genotypes and risk of pulmonary
AD (Table 3). Adjusting for age and gender, FasL
−844CC genotype was associated with an increased risk
for pulmonary AD (aOR=2.010, 95 % CI=1.196–3.379,
P=0.008) compared with TT genotype. The C haplotype
remained a significant risk for pulmonary AD (aOR=
1.504, 95 % CI=1.169–1.936, P=0.002), compared with
T haplotype. Fas −1377 AA genotype was also associ-
ated with an increased risk for pulmonary AD (aOR=
1.400, 95 % CI 1.083–1.809, P=0.010) compared with
GG genotype.
Risk of pulmonary AD was evaluated by combining FasL
−844 genotypes and Fas −1377 genotypes (Table 4). FasL
−844CC was still a risk factor for pulmonary AD no matter
what Fas −1377 genotypes was. However, Fas −1377 AAwas
not a risk factor for pulmonary ADwhen FasL −844 genotype
was TT and TC but was a risk factor when FasL −844 geno-
type was CC.
Fas −1377 genotypes showed significant effect modifica-
tion of pulmonary AD risk by FasL −844 genotype by test of
the interaction term adjusting for age, gender, FasL −844, and
Fas −1377 SNP (aOR=1.531, 95 % CI=1.066–2.201, P=
0.021).
The relationships between clinicopathological significance
and the polymorphisms
The relationships between pulmonary AD clinicopathological
parameters and these two SNPs were compared (Table 5).
There were no significant differences between Fas −1377
gene polymorphism and tumor size, differentiation visceral
pleura, stage, lymph node metastasis, and vascular tumor
thrombus, while FasL −844C/T was associated with tumor
stage and lymph node metastasis. CC versus TT was danger-
ous, aOR=2.273 (1.436–3.599), P=0.000; aOR=2.053
(1.297–3.249), and P=0.002, respectively (Table 6).
Table 6 Risk of pulmonary adenocarcinoma stage and lymph node metastasis according to FasL −844 genotypes
Locus Genotypes Stage Lymph node metastasis
Adjusted OR# (95 % CI) P Adjusted OR# (95 % CI) P
FasL −844 TT 1 1
TC 2.573 (1.003–6.601) 0.049* 2.163 (0.844–5.544) 0.108
CC 2.273 (1.436–3.599) 0.000** 2.053 (1.297–3.249) 0.002**
*P<0.05; **P<0.01
#Adjusting for age and gender
Table 7 Genotypic and allelic frequencies of FasL −844 and Fas −1377 in subgroups according to age
Number (%) Age Smoking status Gender FasL −844 genotypes Fas −1377 genotypes
<60 No Yes Male Female TT TC CC GG GA AA
Cases (n=119) 109 (91.6) 10 (8.4) 62 (52.1) 57 (47.9) 12 (10.1) 43 (36.1) 64 (53.8) 41 (34.5) 48 (40.3) 30 (25.2)
Controls (n=192) 170 (88.5) 22 (11.5) 114 (59.4) 78 (40.6) 35 (18.3) 83 (43.2) 74 (38.5) 78 (40.6) 88 (45.8) 26 (13.5)
χ2 0.74 1.582 7.983 6.794
P 0.39 0.208 0.018* 0.033*
≥60
Cases (n=156) 110 (70.5) 46 (29.5) 85 (54.5) 71 (45.5) 20 (12.8) 60 (38.5) 76 (48.7) 48 (30.8) 85 (54.5) 23 (14.7)
Controls (n=105) 64 (61.0) 41 (39.0) 65 (61.9) 40 (38.1) 17 (16.2) 45 (42.9) 43 (41.0) 43 (41.0) 50 (47.6) 12 (11.4)
χ2 2.58 1.413 1.634 2.953
P 0.11 0.235 0.442 0.228
*P<0.05; **P<0.01
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Association of the polymorphisms and pulmonary AD
stratified by age
Patients with pulmonary AD and healthy group were
stratified by age to explore whether FasL −844T/C and
Fas −1377G/A polymorphisms were associated with pul-
monary AD in this selected population of patients
(Table 7). The two genotype frequencies in two control
subgroups (<60 and ≥60 years old) agreed with frequen-
cies expected under the Hardy–Weinberg equilibrium
(χ2=1.852, P=0.174 and χ2=0.792, P=0.373 for FasL
−844C/T; χ2=0.022, P=0.881 and χ2=0.197, P=0.657
for Fas −1377G/A, respectively).
With age <60 years, the frequencies of the TT, TC,
and CC of FasL −844 genotypes were 10.1, 36.1, and
53.8 %, respectively, among the cases and 18.2, 43.2,
and 38.5 %, respectively, among the controls, which had
statistical difference (χ2=7.983, P=0.018). The geno-
type frequencies of Fas −1377 also had statistical dif-
ference (χ2=6.794, P=0.033). In main effect analysis,
FasL −844 and Fas −1377 SNPs in <60 subgroups were
associated with increased risk of pulmonary AD suscep-
tibility (Table 8).
For those over age 60, there were no differences between
the two groups about genotypes or alleles.
We conducted further analyses to explore whether FasL
−844T/C polymorphism was associated with clinicopatholog-
ical parameters in the selected population of patients (Table 9).
For those <60 years, FasL −844T/C showed significant asso-
ciation with tumor stage (crude OR=1.974, 95 % CI 1.113–
3.502, P=0.020; aOR by smoking and sex=1.995, 95 % CI=
1.098–3.627, P=0.023). For those ≥60 years, FasL −844T/C
showed significant associations with stage (crude OR=2.119,
95 % CI 1.301–3.451, P=0.003; adjust OR by smoking and
sex=2.228, 95 % CI 1.351–3.675, P=0.002) and lymph node
metastasis (crude OR=2.051, 95 % CI 1.252–3.361, P=
0.004; adjust OR by smoking and sex=2.123, 95 % CI=
1.285–3.508, P=0.003).
Discussion
Fas–FasL system plays an important role in regulating apo-
ptosis and maintaining cellular homeostasis. FasL is an impor-
tant gene in lung AD. Nineteen genes were designated as
candidate lung tumor progression (LTP) genes because their
expression changes may specially affect lung tumor progres-
sion in mice. FasL was the most important gene among these
LTP genes [17].
Fas and FasL genes are located on chromosomes 10q24.1
and 1q23, respectively. Fas −1377 polymorphism is in tight
linkage disequilibrium with FAS −670 polymorphisms. Fas
−1377A allele disrupts Sp1 transcription factor binding sites,
and FAS −670G allele abolishes STAT1-binding sites, both of
which diminish Fas promoter activity and decrease gene ex-
pression [11]. FasL −844T/C polymorphism is located in the
Table 8 Main effects of individual risk factors on pulmonary























aAdjusting for gender, smoking and Fas −1377 locus
bAdjusting for gender, smoking and FasL −844 locus
Table 9 Distribution of selected characteristics of patient subgroup cohort
<60 ≥60
FasL −844 Fas −1377 FasL −844 Fas −1377
χ2 P χ2 P χ2 P χ2 P
Smoking 1.495 0.473 4.046 0.132 1.615 0.446 0.825 0.662
Gender 1.265 0.531 0.031 0.985 1.206 0.574 0.782 0.677
Tumor length 2.064 0.356 0.477 0.788 0.623 0.732 0.207 0.122
Differentiation 1.848 0.397 0.174 0.917 0.477 0.788 2.094 0.351
Visceral pleura 0.13 0.931 0.609 0.738 0.797 0.671 0.442 0.802
Stage 6.471 0.039* 2.069 0.355 9.594 0.008* 0.073 0.964
Lymph node metastasis 4.152 0.125 0.848 0.654 8.823 0.012* 0.001 1.000
Vascular tumor thrombus 3.588 0.166 4.216 0.121 0.019 0.991 2.934 0.231
*P<0.05
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gene promoter. Higher basal expression of FasL is significant-
ly associated with FasL −844C allele compared with FasL
−844Tallele. The C allele and its flanking sequence constitute
CAAT box which is the binding site for CAAT Enhancer
Binding Protein Beta (C/EBPb), resulting in a significantly
higher basal FasL expression [16, 18]. FasL −844T/C poly-
morphism may influence FasL expression level and FasL-
mediated signaling pathway, and ultimately, the susceptibility
to cancer.
Fas–FasL system involves in immune escape with two
kinds of mechanisms: FasL on tumor cells cross-links with
Fas on tumor-infiltration lymphocyte (TIL) to induce TIL ap-
optosis [19–22]. Meanwhile, TIL in tumor microenvironment
can kill each other through AICD by Fas–FasL pathway [23,
24]. Fas can regulate apoptosis effect of FasL. In our study,
both FasL −844T/C and Fas −1377G/A polymorphisms were
associated with the susceptibility of pulmonary AD. However,
only when FasL −844 genotype was CC, Fas −1377GGwas a
risk factor for lung AD, and Fas −1377 genotypes showed
significant effect modification of pulmonary AD risk by FasL
−844 genotype, which is consistent with the mechanism.
Sung et al. studied the association of FasL −844CC SNPs
with NSCLC in Taiwan [25]. They found that the FasL
−844T/C genotype was not associated with lung cancer risk
in case–control study. Ter-Minassian et al. studied the associ-
ation of these SNPs with NSCLC in a large case–control study
in Canada [26]. No associations with NSCLC were observed
in the main effects analysis for FasL −844C/T and Fas
−1377G/A adjusting for age, gender, smoking status, pack-
years, and years since smoking cessation. In subjects under
age 60, for FasL −844C/T polymorphism, CT compared with
the CC genotype was significantly associated with increased
risk of NSCLC. Zhang et al. examined the contribution of
these polymorphisms to risk of developing lung cancer in
northern China [27]. Compared with noncarriers, there was a
1.59-fold excess risk of developing lung cancer for carriers of
the Fas −1377AA genotype and 1.79-fold excess risk for car-
riers of FasL −844CC. Fas and FasL genotypes were deter-
mined in 582 lung cancer patients and 582 healthy control
subjects who were frequency-matched for age and gender in
Korea [28]. Both genotypes and Fas haplotypes exhibited no
apparent relationship with the risk of lung cancer. In addition,
there was no significant interaction between Fas and FasL
polymorphisms in the development of lung cancer. The results
suggested that Fas −1377G/A and −670A/G and FasL −844T/
C polymorphisms did not significantly affect the susceptibility
to lung cancer in Koreans.
We investigated the association between FasL −844T/C
and Fas −1377 polymorphism on the risk of pulmonary AD
in South China population. In this study, FasL −844 and Fas
−1377 genotypes were risk factors for pulmonary AD. Further-
more, FASL −844CC and Fas −1377GG were risk factors for
pulmonary AD by genotypes analyses. These two genotypes
were risk factors for patients <60 years old and did not increase
the risk of disease in patients ≥60, suggesting that patients
<60 years old had strong immune function and immune sup-
pression may increase the risk of cancer, while being ≥60 with
weak immune function suffering a certain degree of immuno-
suppression did not increase the risk of cancer. Fas −1377, only
in the present of FasL −844CC genotype, could increase the
risk of cancer. Fas −1377 genotypes showed significant effect
modification of pulmonary AD risk by FasL −844 genotype by
test of the interaction term adjusting for age, gender, FasL
−844, and Fas −1377 SNP. This result verifies the mechanism
of Fas–FasL-mediated cell apoptosis: FasL can induce cell ap-
optosis by cross-linking with Fas.
It had been shown that Fas expression did not correlate
with age, sex, histological type, or stage of disease. However,
NSCLC expressing FasL was associated with poor clinical
prognosis and metastasis [25]. Sung et al. found that the FasL
−844CC genotype had higher prevalence in those with ad-
vanced tumors than in those with early tumors. Not only did
we find that FasL −844CC is associated with stage of pulmo-
nary AD but also we found that this genotype is the risk factor
for lymph node metastasis, especially in patients for age equal
and over 60 years. So, pulmonary AD cells with FasL
−844CC may have strong invasiveness.
Conclusions
In conclusion, FasL −844 and Fas −1377 genotypes were risk
factors for pulmonary AD for patients <60 old. Fas −1377,
only in the present of FasL −844CC genotype, could increase
the risk of cancer. Fas −1377 genotypes showed significant
effect modification of pulmonary AD risk by FasL −844 ge-
notype by test of the interaction term. FasL −844CCwas a risk
factor for tumor stage and lymph node metastasis. Therefore,
FasL −844 genotype plays an important role in the occurrence
and progression of pulmonary AD.
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